GSK Expands Share Buyback Program with Recent Purchase

GlaxoSmithKline ( (GB:GSK) ) has shared an announcement.

GSK plc has announced the purchase of 483,823 of its own ordinary shares as part of its ongoing buyback program, executed through Merrill Lynch International. This transaction, which took place on June 23, 2025, is part of a non-discretionary agreement with the broker and contributes to the company’s strategy to manage its capital structure. Following this purchase, GSK holds 223,761,425 shares in treasury, with 4,091,584,047 shares in issue. The buyback program may impact shareholder value and voting rights, as the percentage of voting rights attributable to treasury shares is now 5.47%.

The most recent analyst rating on (GB:GSK) stock is a Buy with a £2610.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.

Spark’s Take on GB:GSK Stock

According to Spark, TipRanks’ AI Analyst, GB:GSK is a Outperform.

GlaxoSmithKline demonstrates solid financial performance and strategic growth initiatives. Despite leverage concerns, the company’s commitment to innovation and shareholder returns, coupled with a fair valuation, supports a favorable stock outlook. Mixed technical signals suggest caution in the short term, but long-term prospects are bolstered by robust earnings and corporate actions.

To see Spark’s full report on GB:GSK stock, click here.

More about GlaxoSmithKline

GlaxoSmithKline (GSK) is a global healthcare company operating in the pharmaceutical industry, known for its development and production of medicines, vaccines, and consumer healthcare products. The company focuses on improving the quality of human life by enabling people to do more, feel better, and live longer.

Average Trading Volume: 10,173,457

Technical Sentiment Signal: Hold

Current Market Cap: £56.79B

Learn more about GSK stock on TipRanks’ Stock Analysis page.